Amniotics AB (publ) develops stem cell-based therapeutics to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; CutiStem for the treatment of dermatological indications; and AMNI-NK003. The company offers contract development and contract manufacturing services for advanced therapy medicinal products to the pharmaceutical industries, universities, and hospitals. Amniotics AB (publ) was incorporated in 2015 and is based in Lund, Sweden.

執行長

Mr. Marcus Larsson Ph.D.

員工

國家

Sweden

上市

0 Comments

分享你的想法

FAQ

Amniotics AB 今天的股價是多少？▼

AMNI.ST 目前價格為 SEK0.01 SEK，過去 24 小時上漲了 +5.88%。在圖表上更密切關注 Amniotics AB 股價表現。

Amniotics AB 的股票代號是什麼？▼

根據交易所不同，股票代號可能會有所差異。例如，在交易所，Amniotics AB 的股票以代號 AMNI.ST 進行交易。

Amniotics AB 有多少名員工？▼

截至 April 01, 2026，公司共有 4 名員工。

Amniotics AB 位於哪個產業？▼

Amniotics AB從事於Healthcare產業。

Amniotics AB 何時完成拆股？▼

Amniotics AB 最近沒有進行任何拆股。

Amniotics AB 的總部在哪裡？▼

Amniotics AB 的總部位於 Sweden 的 Lund。